JP Morgan Chase’s Eikon Therapeutics EIKN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$450K Buy
56,951
+46,627
+452% +$469K ﹤0.01% 5295
2026
Q2
$132K Buy
10,324
+9,024
+694% +$92.1K ﹤0.01% 5846
2026
Q1
$12.6K Buy
+1,300
New +$17.4K ﹤0.01% 6675

Other funds holding EIKN

JP Morgan Chase's EIKN Position: Q3 2026 in Review

JP Morgan Chase increased its Eikon Therapeutics (EIKN) stake by 452% in Q3 2026, buying an estimated $469K and bringing the position to 56,951 shares worth $450K. The position accounts for ﹤0.01% of the portfolio, ranked #5295.

JP Morgan Chase first reported a position in EIKN in Q1 2026 and has held it in 3 quarters since. 74 funds tracked by Wall St. Rank hold EIKN as of Q3 2026.

  • JP Morgan Chase held 56,951 shares of Eikon Therapeutics worth $450K as of Q3 2026.
  • JP Morgan Chase bought 46,627 Eikon Therapeutics shares in Q3 2026, an estimated $469K.
  • Eikon Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q3 2026, its #5295 holding.
  • JP Morgan Chase first reported a position in Eikon Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 74 funds tracked by Wall St. Rank held Eikon Therapeutics as of Q3 2026.

Based on JP Morgan Chase's 13F filing for Q3 2026, filed 12 Nov 2026.